Table 3.
Cardiovascular and diabetes biochemical markers in PLWH with and without MetS
| MetS (n = 29) | No MetS (n = 60) | P value | |
|---|---|---|---|
| T-Chol (mg/dl) | 184 ± 41 | 182 ± 36 | 0.83 |
| LDL-C (mg/dl) | 110 ± 31 | 107.34 | 0.71 |
| HDL-C (mg/dl) | 46 ± 15 | 53 ± 15 | 0.07 |
| VLDL-C (mg/dl) | 28 ± 17 | 22 ± 12 | 0.12 |
| Non-HDL-C (mg/dl) | 138 ± 35 | 130 ± 38 | 0.32 |
| Total/HDL-C | 4.2 ± 1.1 | 3.7 ± 1.3 | 0.09 |
| TGs (mg/dl) | 139 ± 84 | 112 ± 56 | 0.13 |
| CRP (mg/L) | 6.5 ± 8.3 | 5.3 ± 7.3 | 0.52 |
| FG (mg/dl) | 103 ± 51 | 91 ± 10 | 0.21 |
| HbA1C (%; mmol/mol)* | 6.4;46 | 5.7;39 | 0.03 |
| Insulin (μU/mL) | 17.3 ± 13.1 | 13.4 ± 7.6 | 0.15 |
| Insulin resistance (HOMA) | 4.3 ± 3.4 | 3.0 ± 1.9 | 0.09 |
Data are means ± SD. *SDs for HbA1C are 1.7 (MetS) and 0.6 (No MetS).
PLWH people living with HIV, MetS metabolic syndrome, T-Chol total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, VLDL-C very-low density lipoprotein cholesterol, TGs triglycerides, CRP C-reactive protein, FG fasting glucose, HbA1C hemoglobin A1C, HOMA homeostasis model assessment.